Axial Spondyloarthritis (axSpA) Market Report 2026

Axial Spondyloarthritis (axSpA) Market Overview

• Axial Spondyloarthritis (axSpA) market size has reached to $6.56 billion in 2025 • Expected to grow to $9.83 billion in 2030 at a compound annual growth rate (CAGR) of 8.5% • Growth Driver: Demographic Shifts And The Rising Aging Population Is A Catalyst For Axial Spondyloarthritis (AXSPA) Market Growth • Market Trend: UCB Sa Secures Eu Approval For Bimzelx In Treating Axial Spondyloarthritis (AXSPA) • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Axial Spondyloarthritis (axSpA) Market?

Axial spondyloarthritis (axSpA) is a chronic inflammatory condition that predominantly impacts the axial skeleton, encompassing the spine and sacroiliac joints. It is characterized by inflammation in the sacroiliac joints, resulting in persistent back pain and stiffness. The main types of axial spondyloarthritis (axSpA) are ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA). Ankylosing spondylitis (AS) refers to a form of arthritis that damages the ligaments and joints in the spine, where over-the-counter anti-inflammatory medications, such as naproxen and ibuprofen, are commonly used to relieve pain, inflammation, and muscle stiffness to delay complications and spinal deformities. The various commercialized therapies include anti-tumor necrosis factor therapy (TNF), anti-interleukin therapy (IL), and anti-janus kinase therapy (JAK) in different dosage forms such as tablets and injections for different types of treatments such as tumor necrosis factor (TNF) alpha inhibitors, non-steroidal anti-inflammatory drugs (NSAID), conventional disease modifying anti-rheumatic drugs, glucocorticoids, and interleukin blockers. These are sold by different end-users such as hospital pharmacies, retailer pharmacies, and online pharmacy stores.

What Is The Axial Spondyloarthritis (axSpA) Market Growth Forecast?

The axial spondyloarthritis (axspa) market size is expected to see strong growth in the next few years. It will grow to $9.83 billion in 2030 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to increasing adoption of JAK inhibitors and IL therapies, rising investments in personalized medicine, expansion of early screening programs, growing use of digital disease monitoring platforms, continued innovation in biologic drug development. Major trends in the forecast period include increasing adoption of biologic therapies, rising use of targeted anti-inflammatory drugs, growing focus on early diagnosis and disease monitoring, expansion of personalized treatment approaches, enhanced integration of digital health tools.

Global Axial Spondyloarthritis (axSpA) Market Segmentation

1) By Type: Ankylosing Spondylitis (AS), Non-Radiographic Axial Spondyloarthritis (nr-axSpA) 2) By Commercialized Therapies: Anti-Tumor Necrosis Factor Therapy (TNF), Anti-Interleukin Therapy (IL), Anti-Janus Kinase Therapy (JAK) 3) By Dosage Form: Tablets, Injections 4) By Treatment: Tumor Necrosis Factor (TNF) Alpha Inhibitors, Non-Steroidal Anti-Inflammatory Drugs (NSAID), Interleukin Blockers 5) By End-Use: Hospital Pharmacies, Retailer Pharmacies, Online Pharmacy Stores Subsegments: 1) By Ankylosing Spondylitis (AS): Early-stage AS, Advanced-stage AS 2) By Non-Radiographic Axial Spondyloarthritis (nr-axSpA): Active nr-axSpA, Low-Disease-Activity nr-axSpA

What Is The Driver Of The Axial Spondyloarthritis (axSpA) Market?

The increasing aging population is expected to propel the growth of the axial spondyloarthritis (axSpa) market going forward. Aging population refers to a demographic trend characterized by an increasing proportion or a higher percentage of elderly individuals within a population. The benefits of addressing and managing axSpA in the aging population include improved joint function and mobility, improved quality of life, prevention of structural damage to the spine, reduced healthcare costs, prevention of disability, and optimized treatment strategies. For instance, in 2023, according to Age UK, a UK-registered charity, reports that in 2023 there are 11 million people aged over 65 in England. This is projected to increase by 10% in the next five years and by 32% by 2043 (1.1 and 3.5 million people, respectively). The population aged 85+, the age group most likely to need health and care services, is also projected to rise rapidly, increasing by 8.2% in the next five years and by 62.7% by 2043 (126,000 and 956,000 people, respectively). Therefore, the increasing aging population is driving the growth of the axial spondyloarthritis (axSpa) industry.

Key Players In The Global Axial Spondyloarthritis (axSpA) Market

Major companies operating in the axial spondyloarthritis (axspa) market are AbbVie Inc., Pfizer Inc., Novartis AG, Eli Lilly and Company, Johnson & Johnson, UCB S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Sanofi S.A., Regeneron Pharmaceuticals Inc., Merck & Co. Inc., GSK plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Biogen Inc., Amgen Inc., Chugai Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Corporation, Kyowa Kirin Co. Ltd., Janssen Pharmaceuticals, Acelyrin Inc.

Global Axial Spondyloarthritis (axSpA) Market Trends and Insights

Major companies operating in the axial spondyloarthritis (axSpA) market are focusing on developing innovative solutions, such as next-generation biologic drug therapies, to meet the rising demand for effective treatments that target inflammation and improve long-term disease control. These biologic therapies modulate specific immune pathways and offer a more targeted approach compared with traditional anti-inflammatory drugs, which primarily address symptoms without directly influencing underlying immune drivers. For instance, in June 2023, UCB SA, a Belgium-based pharmaceutical company, received approval from the New European Commission for the marketing authorization of BIMZELX (bimekizumab). This medication is used to treat adults with active axial spondyloarthritis (axSpA), non-radiographic axial spondyloarthritis (nr-axSpA), and ankylosing spondylitis (AS) with objective signs of inflammation as indicated by elevated C-reactive protein. These European Union (EU) authorizations represent the drug's first global marketing licenses for axial spondyloarthritis.

What Are Latest Mergers And Acquisitions In The Axial Spondyloarthritis (axSpA) Market?

In July 2024, Spine BioPharma, a US-based biopharmaceutical company, partnered with Ensol BioSciences to advance the development of SB-01 for fibrotic diseases, including axial spondyloarthritis (axSpA). With this partnership, the companies aim to expand SB-01’s therapeutic potential into fibrosis-driven musculoskeletal conditions, supporting clinical development and accelerating pathways toward commercialization in axSpA and related indications. Ensol BioSciences is a South Korea-based biotechnology company specializing in protein-based drug discovery and development.

Regional Outlook

North America was the largest region in the axial spondyloarthritis(axSpA) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Axial Spondyloarthritis (axSpA) Market?

The axial spondyloarthritis (axSpA) market consists of revenues earned by entities by providing physical examinations, blood tests, magnetic resonance imaging (MRI) scans, and X-ray scans. The market value includes the value of related goods sold by the service provider or included within the service offering. The axial spondyloarthritis (axSpA) market also includes sales of analgesics, biologics, ibuprofen, naproxen, and diclofenac. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Axial Spondyloarthritis (axSpA) Market Report 2026?

The axial spondyloarthritis (axspa) market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the axial spondyloarthritis (axspa) industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.